InflaRx NV (IFRX)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
InflaRx NV Analyst Rating
View moreForecast & Rating
Sep 1, 2026Price forecast
$7.93274.00%
Forecast & RatingStrong buy
8analysts
- Strong buy87.50%
- Buy0.00%
- Hold12.50%
- Sell0.00%
- Strong sell0.00%
News
- Quartr · 4 hours ago
IFRX: Renal focus and strong clinical data position izicopan for major market opportunity after competitor exit
- benzinga_article · 7 hours ago
This GE Vernova Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
- PUBT · Aug 20 at 11:30 AM
InflaRx to present at H.C. Wainwright Annual Global Investment Conference
- Market Beat · Aug 7 at 12:36 PM
Cantor Fitzgerald Increases InflaRx (NASDAQ:IFRX) Price Target to $6.00
- TradingKey · Aug 6 at 12:24 PM
InflaRx Q2 2026 earnings: Lower costs narrow the operating loss
